

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

	)	
THERAVANCE BIOPHARMA R&D IP,	)	
LLC, THERAVANCE BIOPHARMA US,	)	
INC., THERAVANCE BIOPHARMA	)	
IRELAND LIMITED, MYLAN	)	
IRELAND LIMITED, and MYLAN	)	
SPECIALTY L.P.,	)	C.A. No.
	)	
Plaintiffs,	)	
	)	
v.	)	
	)	
LUPIN INC., LUPIN LTD., and LUPIN	)	
PHARMACEUTICALS, INC.,	)	
	)	
Defendants.	)	

**SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN  
ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs Theravance Biopharma R&D IP, LLC, Theravance Biopharma Ireland Limited, Theravance Biopharma US, Inc., Mylan Ireland Limited, and Mylan Specialty L.P. (collectively, “Plaintiffs”), hereby provide the information below with respect to the deadlines set forth in 21 U.S.C. § 355(j):

Date Patentee(s) Received Notice:	No earlier than January 12, 2023
Date NDA Holder Received Notice:	No earlier than January 6, 2023
Date of Expiration of Patents:	8/25/2031 (8,541,451) 7/14/2030 (9,765,028) 7/14/2030 (10,550,081) 7/14/2030 (11,008,289) 10/23/2039 (11,484,531)
Thirty Month Stay Deadline:	*May 9, 2026

\* Calculated pursuant to New Chemical Entity status (21 U.S.C. § 355(j)(5)(F)(ii)).

Dated: February 17, 2023

Respectfully submitted,

/s/ Mary W. Bourke

Mary W. Bourke (#2356)

Dana K. Severance (#4869)

Ben Bourke (#6534)

WOMBLE BOND DICKINSON (US) LLP

1313 North Market Street, Suite 1200

Wilmington, DE 19801

(302) 252-4320

Mary.Bourke@wbd-us.com

Dana.Severance@wbd-us.com

Ben.Bourke@wbd-us.com

*Attorneys for Plaintiffs*

*Theravance Biopharma R&D IP, LLC,*

*Theravance Biopharma Ireland Limited, and*

*Theravance Biopharma US, Inc.*

/s/ Stamatios Stamoulis

Stamatios Stamoulis (#4606)

STAMOULIS & WEINBLATT LLC

800 North West Street, Third Floor

Wilmington, DE 19801

(302) 999-1540

stamoulis@swdelaw.com

*Attorneys for Plaintiffs*

*Mylan Ireland Limited and Mylan Specialty*

*L.P.*